HPGC Renmintongtai Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Weidong Zhu

Chief Executive Officer (CEO)

CN¥1.2m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	9.7yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.7yrs
Promedio de permanencia en la Junta Directiva	1.6yrs

Actualizaciones recientes de la dirección

Recent updates

Is HPGC Renmintongtai Pharmaceutical (SHSE:600829) A Risky Investment?

Oct 01

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Might Be Having Difficulty Using Its Capital Effectively

Sep 05

CEO

Weidong Zhu (55 yo)

9.7yrs

Permanencia

CN¥1,232,100

Compensación

Mr. Weidong Zhu served as Deputy General Manager at HPGC Renmintongtai Pharmaceutical Corporation. Mr. Zhu serves as Deputy General Manager and General manager of Harbin Renmintongtai Pharmacy chain stores...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Weidong Zhu	GM & Chairman	no data	CN¥1.23m	sin datos
Ping Guan	Deputy GM & CFO	2.6yrs	CN¥645.00k	sin datos
Cong Feng Gu	Deputy GM & Director	no data	CN¥985.00k	sin datos
Lei Wang	Board Secretary	2.7yrs	CN¥217.20k	sin datos
Jin Zhang	Chief Accountant	9.7yrs	CN¥176.80k	sin datos

2.7yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 600829 se considera experimentado (2.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Weidong Zhu	GM & Chairman	9.7yrs	CN¥1.23m	sin datos
Cong Feng Gu	Deputy GM & Director	no data	CN¥985.00k	sin datos
Xiaodong Meng	Chairman of the Supervisory Board	2.3yrs	sin datos	sin datos
Bin Wu	Independent Director	5.3yrs	CN¥80.00k	sin datos
Peng Yuan Cheng	Director	less than a year	sin datos	sin datos
Dan Guo	Independent Director	less than a year	sin datos	sin datos
Shiwei Yin	Director	less than a year	sin datos	sin datos

1.6yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 600829 no se considera experimentada (1.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.

HPGC Renmintongtai Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

HPGC Renmintongtai Pharmaceutical Corporation, Annual General Meeting, Jun 06, 2024

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 16%

Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.15 in 3Q 2023)

Is HPGC Renmintongtai Pharmaceutical (SHSE:600829) A Risky Investment?

New minor risk - Share price stability

HPGC Renmintongtai Pharmaceutical Corporation to Report Q3, 2024 Results on Oct 22, 2024

Investor sentiment improves as stock rises 21%

HPGC Renmintongtai Pharmaceutical (SHSE:600829) Might Be Having Difficulty Using Its Capital Effectively

Investor sentiment improves as stock rises 22%

Second quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.14 in 2Q 2023)

HPGC Renmintongtai Pharmaceutical Corporation to Report First Half, 2024 Results on Aug 09, 2024

HPGC Renmintongtai Pharmaceutical Corporation, Annual General Meeting, Jun 06, 2024

HPGC Renmintongtai Pharmaceutical Corporation to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.45 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

HPGC Renmintongtai Pharmaceutical Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022)

HPGC Renmintongtai Pharmaceutical Corporation to Report Q3, 2023 Results on Oct 25, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 27%

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.10 in 2Q 2022)

HPGC Renmintongtai Pharmaceutical Corporation to Report First Half, 2023 Results on Aug 12, 2023

Full year 2022 earnings released: EPS: CN¥0.45 (vs CN¥0.48 in FY 2021)

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.48 in FY 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.17 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.17 in 2Q 2021)

Full year 2021 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.056 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.069 (vs CN¥0.083 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.25 (vs CN¥0.46 in FY 2019)

New 90-day low: CN¥5.79

HPGC Renmintongtai Pharmaceutical Corporation to Report Fiscal Year 2020 Results on Mar 20, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥6.62

New 90-day high: CN¥7.77

New 90-day low: CN¥7.10

Third quarter earnings released

HPGC Renmintongtai Pharmaceutical Corporation to Report Q3, 2020 Results on Oct 17, 2020

New 90-day low: CN¥7.28

Earnings released

New 90-day high - CN¥8.53

HPGC Renmintongtai Pharmaceutical Corporation to Report First Half, 2020 Results on Aug 15, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad